Febraayo 2022: Dalka Shiinaha, bukaan noloshiisu ay qarka u saarnayd inay dhammaato ayaa gabi ahaanba laga bogsaday cudurka leukemia-ga mahaddana CAR T-cell daaweynta, taasoo kicisay habdhiska difaaca. Dhammaan unugyada kansarka ayaa si degdeg ah u baab'ay daraasaddii ugu horreysay ee nooceeda ah. Daaweyn dhexdhexaadin ah, oo ay hormuud ka ahaayeen Maraykanka saynisyahano ACGT sida Dr. Carl June oo ka tirsan Jaamacadda Pennsylvania iyo Dr. Michel Sadelain oo ka tirsan Xarunta Kansarka Memorial-Sloan Kettering, iyo kuwo kale, ayaa si degdeg ah u caddaynaysa guulo badan tijaabooyin aadanaha oo kumanaan bukaan ah.
Ka dib markii lagu daweeyay daawaynta unugyada CAR T-cell, haweeney da' dhexaad ah ayaa la sheegay in laga daweeyay leukemia. - Unugyadii kansarka ee jidhkeeda way libdheen. Professor Qian Cheng, oo ah maamulaha Xarunta Daaweynta Biyo-nololeedka ee cisbitaalka Chongqing, ayaa yiri, "Iyadu waa bukaankii ugu horreeyay ee si buuxda looga daaweeyay xaaladda iyada oo loo marayo daawaynta hidda-wadaha."
Leukemia waxaa laga helay ku dhawaad afar milyan oo qof oo Shiinaha ah. Daaweynta CAR T waa daawayn hidde-side ah oo adeegsata unugyada T-da ee la beddelay si ay ula dagaallamaan unugyada kansarka ee bukaannada leukemia-ga. Bukaanjiifka badankooda waxaa lagu daweeyaa kiimoterabi ama beeris dhuuxa lafta. "Daaweynta CAR T waa bedel aad u wanaagsan," Professor Qian ayaa yiri, "maxaa yeelay waxay hoos u dhigi kartaa kharashyada ugu yaraan 30% marka la barbardhigo dhuuxa lafta ku-tallaalidda waxayna u badan tahay inay horseeddo daawo."
Sida laga soo xigtay Professor Qian, lix bukaan oo kale oo lagu daweynayo hiddo-wadaha isla machad ayaa hagaajiyay caafimaadkooda. Dalka Shiinaha, daawaynta hidda-wadaha CAR T ayaa wali ku jirta marxaladda tijaabada caafimaad, iyadoo toban isbitaal oo dalka oo dhan ah ay heleen. Guushu waxay dhiirigelisay kooxda Qian, kuwaas oo sii wadi doona cilmi-baarista qiyaasaha si ay u horumariyaan daawada cusub.
